GlassScriptPhysician profile
Lezlie Malson
NPI 1073968657
$9,031.59
in general payments reported to CMS, 2019-2025
44 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,901 · 2022: $1,772 · 2023: $1,982 · 2024: $2,300 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,357.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,546.71 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $890.71 | 2021-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $804.40 | 2021-2025 | |
| Pfizer INC. | $631.93 | 2021-2025 | |
| Lilly USA, LLC | $598.53 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $429.76 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.67 | 2021-2025 | Jardiance, Ofev, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $318.89 | 2021-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Janssen Pharmaceuticals, INC | $272.31 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $252.19 | 2022-2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $250.67 | 2021-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $249.56 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $214.03 | 2021-2024 | |
| Amarin Pharma, INC. | $192.03 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $190.32 | 2024 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $179.65 | 2021-2023 | Seglentis, Livalo |
| Dexcom, INC. | $156.60 | 2023-2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $154.02 | 2023-2025 | Sunosi, Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $141.28 | 2021-2024 | Trintellix |
| Jazz Pharmaceuticals INC. | $111.14 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $108.23 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $102.62 | 2021 | |
| Exact Sciences Corporation | $93.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Collegium Pharmaceutical, INC. | $88.98 | 2021-2025 | Xtampza |
| Eisai INC. | $76.56 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.77 | 2022 | |
| Baxter Healthcare | $61.88 | 2022 | |
| Almatica Pharma LLC | $49.88 | 2021 | |
| Sumitomo Pharma America, INC. | $47.40 | 2024 | Gemtesa |
| Averitas Pharma INC. | $44.82 | 2023-2024 | Qutenza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.81 | 2022 | |
| Inspire Medical Systems, INC. | $43.44 | 2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $36.99 | 2021-2022 | |
| Corcept Therapeutics | $31.27 | 2025 | Korlym |
| Abbott Laboratories | $28.86 | 2022-2024 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $22.89 | 2023 | Thinprep 2000 Processor, Aptima |
| Corium, LLC | $22.64 | 2023 | Azstarys |
| Viatris Specialty LLC | $22.59 | 2025 | Yupelri |
| Lundbeck LLC | $20.41 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $20.31 | 2024 | Nexletol |
| Sanofi Pasteur INC. | $17.75 | 2023 | |
| Seqirus USA INC | $16.41 | 2022 | |
| Ibsa Pharma INC. | $13.41 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lezlie Malson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.